zileuton 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
5-lipo-oxygenase inhibitors, anti-inflammatory	2862	111406-87-2

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zileuton
leutrol
A-64077
A 64077

an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid

Molecular weight: 236.29
Formula: C11H12N2O2S
CLOGP: 2.48
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 66.56
ALOGS: -3.64
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.14 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	169.28 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1996	FDA	CHIESI USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	48.90	37.39	21	378	127540	63361083

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA PE	N0000008683	Decreased Leukotriene Production
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D020024	Leukotriene Antagonists
MeSH PA	D016859	Lipoxygenase Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:49159	leukotriene antagonists
CHEBI has role	CHEBI:49167	anti-asthmatic drugs
CHEBI has role	CHEBI:64964	5delta-lipoxygenase inhibitor
CHEBI has role	CHEBI:173084	ferroptosis inhibitors
FDA MoA	N0000175955	5-Lipoxygenase Inhibitors
FDA EPC	N0000175956	5-Lipoxygenase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-allergic asthma	indication	266361008	DOID:9360
Allergic asthma	indication	389145006	DOID:9415
Asthma management	indication	406162001
Suicidal thoughts	contraindication	6471006
Hallucinations	contraindication	7011001
Mood swings	contraindication	18963009
Feeling agitated	contraindication	24199005
Depressive disorder	contraindication	35489007
Anxiety	contraindication	48694002
Dream disorder	contraindication	85418005
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Tremors	contraindication
Nervousness	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.96	acidic
pKa2	13.02	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Arachidonate 5-lipoxygenase	Enzyme	P09917	LOX5_HUMAN	INHIBITOR	IC50	6.52		CHEMBL	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme	P16050	LOX15_HUMAN		IC50	6.40		CHEMBL
Cysteinyl leukotriene receptor 2	GPCR	Q9NS75	CLTR2_HUMAN		IC50	5.82		WOMBAT-PK
Leukotriene A-4 hydrolase	Enzyme	P09960	LKHA4_HUMAN		IC50	6.07		WOMBAT-PK
Leukotriene B4 receptor 1	GPCR	Q15722	LT4R1_HUMAN		IC50	6.38		CHEMBL
Arachidonate 5-lipoxygenase-activating protein	Cytosolic other	P20292	AL5AP_HUMAN		IC50	5.66		CHEMBL
Bifunctional epoxide hydrolase 2	Enzyme	P34913	HYES_HUMAN		IC50	6.23		CHEMBL
Prostaglandin E synthase	Enzyme	O14684	PTGES_HUMAN		IC50	6.22		CHEMBL
Arachidonate 5-lipoxygenase	Enzyme		LOX5_RAT		IC50	6.85		CHEMBL
Arachidonate 5-lipoxygenase	Enzyme		LOX5_MOUSE		IC50	6.72		CHEMBL

External reference:

ID	Source
4021009	VUID
N0000148478	NUI
D00414	KEGG_DRUG
4021009	VANDF
C0081408	UMLSCUI
CHEBI:10112	CHEBI
CHEMBL93	ChEMBL_ID
DB00744	DRUGBANK_ID
60490	PUBCHEM_CID
C063449	MESH_SUPPLEMENTAL_RECORD_UI
5297	IUPHAR_LIGAND_ID
6595	INN_ID
V1L22WVE2S	UNII
40575	RXNORM
254934	MMSL
5704	MMSL
d04103	MMSL
006297	NDDF
108617005	SNOMEDCT_US
386180009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZYFLO	HUMAN PRESCRIPTION DRUG LABEL	1	10122-901	TABLET	600 mg	ORAL	NDA	14 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	31722-044	TABLET, FILM COATED, EXTENDED RELEASE	600 mg	ORAL	ANDA	25 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	49884-723	TABLET, MULTILAYER, EXTENDED RELEASE	600 mg	ORAL	ANDA	27 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	49884-723	TABLET, MULTILAYER, EXTENDED RELEASE	600 mg	ORAL	ANDA	27 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	51407-741	TABLET, MULTILAYER, EXTENDED RELEASE	600 mg	ORAL	ANDA	17 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	64380-189	TABLET, MULTILAYER, EXTENDED RELEASE	600 mg	ORAL	ANDA	16 sections
Zileuton	Human Prescription Drug Label	1	64980-206	TABLET, EXTENDED RELEASE	600 mg	ORAL	ANDA	18 sections
Zileuton	Human Prescription Drug Label	1	64980-206	TABLET, EXTENDED RELEASE	600 mg	ORAL	ANDA	18 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	66993-485	TABLET, EXTENDED RELEASE	600 mg	ORAL	NDA authorized generic	25 sections
ZILEUTON	HUMAN PRESCRIPTION DRUG LABEL	1	68180-169	TABLET, EXTENDED RELEASE	600 1	ORAL	ANDA	24 sections
Zileuton	HUMAN PRESCRIPTION DRUG LABEL	1	69339-130	TABLET, MULTILAYER, EXTENDED RELEASE	600 mg	ORAL	ANDA	27 sections